Vaxfectin^® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses

详细信息    查看全文

• 作者：Martha Sedegah ; William O. Rogers ; Maria Belmonte ; Arnel Belmonte ; Glenna Banania ; Noelle B. Patterson ; Denis Rusalov ; Marilyn Ferrari ; Thomas L. Richie ; Denise L. Doolan
• 关键词：Malaria ; T cells ; Multi-gene ; Plasmid DNA vaccines ; Immune enhancement
• 刊名：Vaccine
• 出版年：2010
• 出版时间：9 April 2010
• 年：2010
• 卷：28
• 期：17
• 页码：3055-3065
• 全文大小：685 K

文摘

We previously reported the capacity of the cationic lipid-based formulation, Vaxfectin^®, to enhance the immunogenicity and protective efficacy of a low dose plasmid DNA vaccine against Plasmodium yoelii malaria in mice. Here, we have extended this finding to human Plasmodium falciparum genes, evaluating the immune enhancing effect of Vaxfectin^® formulation on a mixture, designated CSLAM, of five plasmid DNA vaccines encoding antigens from the sporozoite (PfCSP, PfSSP2/TRAP), intrahepatic (PfLSA1), and erythrocytic (PfAMA1, PfMSP1) life cycle stages of P. falciparum administered at 2, 10 or 50 μg doses. Vaxfectin^® formulation enhanced both antibody and cellular immune responses to each component of the multi-antigen vaccine mixture, as assessed by ELISA, IFAT, and IFN-γ ELIspot, respectively. There was no apparent antigenic competition, as indicated by comparison of responses induced in mice immunized with PfCSP vs. CSLAM. These data showing that Vaxfectin^® can enhance the immunogenicity of plasmid DNA vaccines administered at low doses per body weight, and in combinations, has important clinical implications for the development of a vaccine against malaria, as well as against other public health threats.